Weekly Gemcitabine and Docetaxel in Refractory Soft Tissue Sarcoma: A Retrospective Analysis
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose The combination of gemcitabine and docetaxel (GD) is used to effectively treat patients with soft tissue sarcoma (STS). It is widely considered that the conventional doses used are too high for long term use and many patients must discontinue GD treatment due to its toxicity. Therefore, to determine the appropriate dose meeting acceptable efficacy results, while minimizing toxic side effects, we treated patients with a weekly infusion of GD (weekly GD). Materials and Methods A total of 22 patients presenting a variety of STSs were treated at Yonsei Cancer Center. All patients had metastatic or recurrent cancer and had previously received doxorubicin and ifosfamide combination chemotherapy. In all cases, gemcitabine (1,000 mg/m2) and docetaxel (35 mg/m2) were administered intravenously on days 1 and 8 of a 21-day cycle. We retrospectively reviewed the medical records of these patients. Results The response rate was 4.5%, with one patient diagnosed with leiomyosarcoma having a partial response, and the disease control rate was 40.9%. The median progression-free survival (PFS)duration was 2.7 months and the PFS was correlated with the treatment response to a weekly GD. The median overall survival (OS) duration was 7.8 months and the OS was correlated with histology. There was no significant difference in OS between patients who received weekly GD as a 2nd line chemotherapy and those who received 3rd line or more. Treatment was generally well tolerated. Conclusion Weekly GD was well tolerated and showed moderate efficacy, indicating that this could be a reasonable option as a salvage treatment for metastatic STS.
Abstract
Purpose The combination of gemcitabine and docetaxel (GD) is used to effectively treat patients with soft tissue sarcoma (STS). It is widely considered that the conventional doses used are too high for long term use and many patients must discontinue GD treatment due to its toxicity. Therefore, to determine the appropriate dose meeting acceptable efficacy results, while minimizing toxic side effects, we treated patients with a weekly infusion of GD (weekly GD). Materials and Methods A total of 22 patients presenting a variety of STSs were treated at Yonsei Cancer Center. All patients had metastatic or recurrent cancer and had previously received doxorubicin and ifosfamide combination chemotherapy. In all cases, gemcitabine (1,000 mg/m2) and docetaxel (35 mg/m2) were administered intravenously on days 1 and 8 of a 21-day cycle. We retrospectively reviewed the medical records of these patients. Results The response rate was 4.5%, with one patient diagnosed with leiomyosarcoma having a partial response, and the disease control rate was 40.9%. The median progression-free survival (PFS)duration was 2.7 months and the PFS was correlated with the treatment response to a weekly GD. The median overall survival (OS) duration was 7.8 months and the OS was correlated with histology. There was no significant difference in OS between patients who received weekly GD as a 2nd line chemotherapy and those who received 3rd line or more. Treatment was generally well tolerated. Conclusion Weekly GD was well tolerated and showed moderate efficacy, indicating that this could be a reasonable option as a salvage treatment for metastatic STS.
참고문헌 (25)
- Patel SR, "Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation", J Clin Oncol, 19, pp.3483~3489 (2001)
- Okuno S, "Phase II trial of gemcitabine in advanced sarcomas", Cancer, 94, pp.3225~3229 (2002)
- van Hoesel QG, "EORTC Soft Tissue and Bone Sarcoma Group", Ann Oncol, 5, pp.539~542 (1994)
- Verweij J, "Randomized phase II study of docetaxel versus doxorubicin in first-and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults : a study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group", J Clin Oncol, 18, pp.2081~2086 (2000)
- Edmonson JH, "Phase II study of docetaxel in advanced soft tissue sarcomas", Am J Clin Oncol, 19, pp.574~576 (1996)
- Köstler WJ, "Docetaxel as rescue medication in anthracycline-and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma : results of a phase II trial", Ann Oncol, 12, pp.1281~1288 (2001)
- Hensley ML, "Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma : results of a phase II trial", J Clin Oncol, 20, pp.2824~2831 (2002)
- Leu KM, "Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma", J Clin Oncol, 22, pp.1706~1712 (2004)
- Spiridonidis CH, "Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies", J Clin Oncol, 16, pp.3866~3873 (1998)
- Georgoulias V, "Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine : a multicenter phase II trial", J Clin Oncol, 17, pp.914~920 (1999)
- Maki RG, "Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas : results of sarcoma alliance for research through collaboration study 002", J Clin Oncol, 25, pp.2755~2763 (2007)
- Therasse P, "European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada", J Natl Cancer Inst, 92, pp.205~216 (2000)
- Shewach DS, "Metabolism of 2', 2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells", Cancer Res, 54, pp.3218~3223 (1994)
- Iwasaki H, "Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells", Blood, 90, pp.270~278 (1997)
- Huang P, "Action of 2', 2'-difluorodeoxycytidine on DNA synthesis", Cancer Res, 51, pp.6110~6117 (1991)
- Ross DD, "Molecular effects of 2', 2'-difluorodeoxycytidine(Gemcitabine)on DNA replication in intact HL-60 cells", Biochem Pharmacol, 48, pp.1619~1630 (1994)
- Schiff PB, "Promotion of microtubule assembly in vitro by taxol", Nature, 277, pp.665~667 (1979)
- Rowinsky EK, "Taxol : the first of the taxanes, an important new class of antitumor agents", Semin Oncol, 19, pp.646~662 (1992)
- Smorenburg CH, "Combination chemotherapy of the taxanes and antimetabolites : its use and limitations", Eur J Cancer, 37, pp.2310~2323 (2001)
- Bay JO, "Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas : a retrospective analysis", Int J Cancer, 119, pp.706~711 (2006)
- Aihara T, "Phase II study of weekly docetaxel in patients with metastatic breast cancer", Ann Oncol, 13, pp.286~292 (2002)
- Schuette W, "Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel", J Clin Oncol, 23, pp.8389~8395 (2005)
- Baker SD, "Comparative pharmacokinetics of weekly and every-three-weeks docetaxel", Clin Cancer Res, 10, pp.1976~1983 (2004)
- Mauri D, "Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: a meta-analysis", Cancer Treat Rev, 36, pp.69~74 (2010)
- Kuroi K, "Weekly schedule of docetaxel in breast cancer : evaluation of response and toxicity", Breast Cancer, 10, pp.10~14 (2003)